Merck & Co., Inc. (MRK)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 130.72 |
| Open | 130.13 |
| Bid | 130.96 x 900 |
| Ask | 131.14 x 900 |
| Day's range | 130.13 - 131.91 |
| 52-week range | 99.14 - 133.10 |
| Volume | |
| Avg. volume | 8,426,142 |
| Market cap | 332.334B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 144.18 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.08 (2.35%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Business Wire
Merck Announces First-Quarter 2024 Financial Results
RAHWAY, N.J., April 25, 2024--Merck Announces First-Quarter 2024 Financial Results
- Business Wire
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
RAHWAY, N.J., April 04, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor KRAS G12C mutations and express PD-L1 (tumor proportion score [TPS] ≥50%).
- Business Wire
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
BASKING RIDGE, N.J. & RAHWAY, N.J., April 03, 2024--REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
© 2024 Yahoo. All rights reserved.